Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, double-blind, randomized study to evaluate the safety and efficacy of the addition of MK-0431 compared with sulfonylurea therapy in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin monotherapy

Next Previous
X
Search
Trial Profile

A multicenter, double-blind, randomized study to evaluate the safety and efficacy of the addition of MK-0431 compared with sulfonylurea therapy in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin monotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitagliptin (Primary) ; Glipizide; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 13 Jun 2019 Trial has been completed in Spain, Denmark and UK according to European Clinical Trials Database record.
    • 08 Feb 2014 Results published in the Drugs and Aging.
    • 29 Jun 2010 Positive results from post-hoc analysis on the composite endpopint of lower blood sugar, no hypglycemia and no weight gain presented at the American Diabetes Association 70th Annual Scientific Sessions (ADA 2010).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top